Test the efficacy and safety of treatments in 2,000 to 3,000 mild to moderate COVID-19 patients in Africa
current phase of drug development
updated 31 Jul 2021
The ANTICOV clinical trial responds to the urgent need to identify treatments that can be used to treat mild and moderate cases of COVID-19 early and prevent spikes in hospitalizations that could overwhelm fragile and already overburdened health systems in Africa.
Launched in November 2020, the trial is being carried out at 19 sites in 13 countries by the ANTICOV consortium, which includes 26 prominent African and global research and development (R&D) organizations, coordinated by the Drugs for Neglected Diseases initiative (DNDi).
Countries hosting ANTICOV clinical trial sites
ANTICOV is an open-label, randomised, comparative, ‘adaptive platform trial’ that will test the safety and efficacy of treatments in 2,000 to 3,000 mild-to-moderate COVID-19 patients. ANTICOV aims to identify early treatments that can prevent progression of COVID-19 to severe disease and potentially limit transmission.
The initial focus of the ANTICOV trial are repurposed drugs where large-scale randomized clinical trials can provide missing efficacy data in mild-to-moderate patients. Safe and affordable repurposed drugs such as amodiaquine, atazanavir/ritonavir, ivermectin, nitazoxanide and ciclesonide are being reviewed.
ANTICOV is an adaptive platform trial, a flexible and innovative trial design that allows for treatments to be added or removed as evidence emerges.
New treatments will be added as evidence of their potential for mild-to-moderate cases emerges. ANTICOV researchers are actively looking to select the most promising treatments from ongoing global scientific efforts with proof of efficacy, in collaboration with the Access to COVID-19 Tools Accelerator (ACT-A) Therapeutics Partnership, co-convened by Unitaid and Wellcome on behalf of the COVID-19 Therapeutics Accelerator.
Major funding for the ANTICOV consortium is provided by the German Federal Ministry of Education and Research (BMBF) through KfW and by the global health agency Unitaid as part of ACT-A. Early support to launch the initiative was provided by the European & Developing Countries Clinical Trials Partnership (EDCTP), under its second programme supported by the European Union with additional funding from the Swedish government, and the Starr International Foundation, Switzerland.
‘We welcome the ANTICOV trial led by African doctors because it will help answer one of our most pressing questions: with limited intensive care facilities in Africa, can we treat people for COVID-19 earlier and stop our hospitals from being overwhelmed?‘Dr John Nkengasong, Director of the Africa Centres for Disease Control and Prevention
‘Treating patients suffering from mild forms of the COVID-19 infection before they evolve into more severe disease and require hospitalisation is a critical challenge around the world. The ANTICOV trial is designed with this objective in mind, aiming to find safe and effective treatments that work for everyone.’Dr Nick Cammack, COVID-19 Therapeutics Accelerator Lead at Wellcome, co-convener of the ACT-Accelerator Therapeutic Partnership, United Kingdom
- ANTICOV website
- Master protocol
- Patient information and consent form
- Standard operating procedures and other resources
News and stories
- 30 July 2021 – ‘A clear demonstration of the capacity in Africa to conduct extremely complex studies’ – Dr John Amuasi on the ANTICOV trial in Ghana
- 29 July 2021 – Recruitment begins in Mozambique for ANTICOV clinical trial of early treatments for COVID-19
- 28 June 2021 – Why Mali joined the ANTICOV clinical trial: A conversation with Dr Samba Sow
- 18 June 2021 – A few moments with an ANTICOV investigator: Dr Bernhards Ogutu in Kenya
- 27 April 2021 – ANTICOV: largest clinical trial in Africa for people with mild COVID-19 to test new drug combination
- 24 November 2020 – Largest clinical trial in Africa to treat COVID-19 cases before they become severe is launched in 13 countries
Get our latest news, personal stories, research articles, and job opportunities.